Jeffrey Rothman

Jeffrey Rothman

Company: Columbia University Medical Center & CSO, Founder Oncogenuity

Job title: Assistant Professor

Seminars:

Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers 1:30 pm

As the landscape of approaches targeting RAS mutated cancers continues to grow, there are a whole host of investigational inhibitors focused on targeting the RAS signaling pathway and the high value targets which exist within. Now more than ever, it is critical to understand the regulatory mechanisms downstream and upstream of RAS and consider the…Read more

day: Day One

Rationale for Complementary Targeting & Peptide Nucleic Acid Oligonucleotide Delivery for Allele-Specific Targeting of KRAS G12D 10:00 am

Reviewing preceding delivery strategies and efforts for improvements rendered to cationic-aliphatic components Proof of principle: In Vitro and In Vivo targeting of BRAF V600E oncogene In vitro studies showing allele-specific targeting of the KRAS G12D oncogene and a nar complete suppression of KRAS G12D transcription, allele-specifically Outlining the downstream suppression of signaling pathways and allele-specific…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.